NURTEC ODT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nurtec Odt, and what generic alternatives are available?
Nurtec Odt is a drug marketed by Biohaven Ireland and is included in one NDA. There are three patents protecting this drug.
This drug has ninety-six patent family members in thirty-four countries.
The generic ingredient in NURTEC ODT is rimegepant sulfate. Additional details are available on the rimegepant sulfate profile page.
DrugPatentWatch® Generic Entry Outlook for Nurtec Odt
Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NURTEC ODT
| International Patents: | 96 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 31 |
| Clinical Trials: | 2 |
| Patent Applications: | 37 |
| Drug Prices: | Drug price information for NURTEC ODT |
| What excipients (inactive ingredients) are in NURTEC ODT? | NURTEC ODT excipients list |
| DailyMed Link: | NURTEC ODT at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NURTEC ODT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Antonios Likourezos | Phase 4 |
| Weill Medical College of Cornell University | Phase 2 |
| Biohaven Pharmaceuticals, Inc. | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for NURTEC ODT
US Patents and Regulatory Information for NURTEC ODT
NURTEC ODT is protected by five US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NURTEC ODT is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NURTEC ODT
Rimegepant for CGRP related disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Rimegepant for CGRP related disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting NURTEC ODT
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Biohaven Ireland | NURTEC ODT | rimegepant sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 212728-001 | Feb 27, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NURTEC ODT
When does loss-of-exclusivity occur for NURTEC ODT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13226361
Estimated Expiration: See Plans and Pricing
Canada
Patent: 65585
Estimated Expiration: See Plans and Pricing
China
Patent: 4136437
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0171620
Estimated Expiration: See Plans and Pricing
Patent: 0191655
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 19448
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 20016
Estimated Expiration: See Plans and Pricing
Patent: 54681
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 5358
Estimated Expiration: See Plans and Pricing
Patent: 1491585
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 20016
Estimated Expiration: See Plans and Pricing
Patent: 54681
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 48111
Estimated Expiration: See Plans and Pricing
Hungary
Patent: 34936
Estimated Expiration: See Plans and Pricing
Patent: 47050
Estimated Expiration: See Plans and Pricing
Israel
Patent: 4272
Estimated Expiration: See Plans and Pricing
Japan
Patent: 08154
Estimated Expiration: See Plans and Pricing
Patent: 76253
Estimated Expiration: See Plans and Pricing
Patent: 15511581
Estimated Expiration: See Plans and Pricing
Patent: 17226693
Estimated Expiration: See Plans and Pricing
Lithuania
Patent: 20016
Estimated Expiration: See Plans and Pricing
Patent: 54681
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 2171
Estimated Expiration: See Plans and Pricing
Patent: 14009544
Estimated Expiration: See Plans and Pricing
Norway
Patent: 35439
Estimated Expiration: See Plans and Pricing
Poland
Patent: 20016
Estimated Expiration: See Plans and Pricing
Patent: 54681
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 20016
Estimated Expiration: See Plans and Pricing
Patent: 54681
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 556
Estimated Expiration: See Plans and Pricing
Patent: 295
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 201404834X
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 20016
Estimated Expiration: See Plans and Pricing
Patent: 54681
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 2076118
Estimated Expiration: See Plans and Pricing
Patent: 2220969
Estimated Expiration: See Plans and Pricing
Patent: 140130140
Estimated Expiration: See Plans and Pricing
Patent: 200016993
Estimated Expiration: See Plans and Pricing
Spain
Patent: 42737
Estimated Expiration: See Plans and Pricing
Patent: 46031
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NURTEC ODT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2441192 | See Plans and Pricing | |
| Slovenia | 2820016 | See Plans and Pricing | |
| South Korea | 101755742 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
